Precure, LLC is building a massive molecular data engine. The company has chosen Helix as its main lab and AI partner for a project that will process one million biospecimens. The goal is clear: make clinical whole genome sequencing and multiomics part of daily patient care at Mayo Clinic and other health systems, not just a research tool.
Precure, LLC is a distinct entity from the existing Precure Research initiative at Mayo Clinic, which continues as an investigator-led program.
Helix is at the center of this effort. The company will provide advanced AI tools to bring genomics into clinical workflows and research based on biomarkers. Helix will also deliver large-scale multiomics capabilities. This includes clinical whole genome sequencing (WGS) and research-grade proteome sequencing, all tied to long-term clinical data and high-performance computing. The aim is to open new paths for prevention, diagnosis, and treatment.
"Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery," said Aaron Mangold, M.D., chief medical officer at Precure, LLC. "We are working to make clinical whole genome sequencing and multi-omics a foundation of care, helping us detect disease sooner and act earlier."
Precure, LLC aims to create one of the world’s largest integrated multi-omics databases by linking data from one million biospecimens with longitudinal clinical information to identify early biological signs of disease.
James Lu, M.D., Ph.D., CEO of Helix, described the long-term vision: "The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care. Helix brings together the laboratory and data capabilities to make this possible at scale."
Precure, LLC is set up as a Mayo Clinic-controlled company. It is designed to responsibly combine population-scale molecular data with long-term clinical records. Any financial returns to Mayo Clinic from this project will go back into its nonprofit mission for patient care, research, and education, as confirmed in official statements to Fierce Biotech.
This partnership marks a real shift in how precision medicine is built. By joining clinical-grade genomics, proteomics, and AI analytics at a huge scale, Precure, LLC and Helix are not just making small steps—they are setting up a new standard for preventive and diagnostic care. The size and scope of this project show what can happen when clinical vision meets technology. The real test will be how these tools get used in everyday care, and whether this model becomes the blueprint for health systems everywhere.
A Mayo Clinic announcement says the project will go beyond genomics. It will also bring in proteomics, AI, and clinical data, with uses in cardiometabolic disease, cancer, neurological disorders, and immune-mediated disease.
